ArticleAmerican journal of translational research2019

Co-occurrence of RUNX1 and ASXL1 mutations underlie poor response and outcome for MDS patients treated with HMAs.

Ping Wu et al.PubMed ↗Full text ↗

No numbers read from the abstract.